Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells

• Published in: Cancer research (Chicago, Ill.) Ill.), 2019-08, Vol.79 (15), p.3851-3861
• Main Authors: Sasaki, Yuka, Fujimori, Hiroaki, Hozumi, Miyuki, Onodera, Takae, Nozaki, Tadashige, Murakami, Yasufumi, Ashizawa, Kazuto, Inoue, Kengo, Koizumi, Fumiaki, Masutani, Mitsuko
• Format: Article
• Language: English
• Subjects: Animals; Cell Line, Tumor; Glycoside Hydrolases - adverse effects; Humans; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Mice; Mice, Nude; Transfection
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-18-1037

Poly (ADP-ribose) glycohydrolase (PARG) is the main enzyme responsible for catabolism of poly (ADP-ribose) (PAR), synthesized by PARP. PARG dysfunction sensitizes certain cancer cells to alkylating agents and cisplatin by perturbing the DNA damage response. The gene mutations that sensitize cancer cells to PARG dysfunction-induced death remain to be identified. Here, we performed a comprehensive analysis of synthetic lethal genes using inducible PARG knockdown cells and identified dual specificity phosphatase 22 (DUSP22) as a novel synthetic lethal gene related to PARG dysfunction. DUSP22 is considered a tumor suppressor and its mutation has been frequently reported in lung, colon, and other tumors. In the absence of DNA damage, dual depletion of PARG and DUSP22 in HeLa and lung cancer A549 cells reduced survival compared with single-knockdown counterparts. Dual depletion of PARG and DUSP22 increased the apoptotic sub-G fraction and upregulated in lung cancer A549, PC14, and SBC5 cells, and inhibited the PI3K/AKT/mTOR pathway in A549 cells, suggesting that dual depletion of PARG and DUSP22 induced apoptosis by upregulating and suppressing the PI3K/AKT/mTOR pathway. Consistently, the growth of tumors derived from double knockdown A549 cells was slower compared with those derived from control siRNA-transfected cells. Taken together, these results indicate that deficiency exerts a synthetic lethal effect when combined with PARG dysfunction, suggesting that DUSP22 dysfunction could be a useful biomarker for cancer therapy using PARG inhibitors. SIGNIFICANCE: This study identified as a novel synthetic lethal gene under the condition of dysfunction and elucidated the mechanism of synthetic lethality in lung cancer cells.